New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?

Author： Sahebkar Amirhossein   Watts Gerald  

Publisher： Springer Publishing Company

ISSN： 0920-3206

Source： Cardiovascular Drugs and Therapy, Vol.27, Iss.6, 2013-12, pp. : 559-567

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

What can we expect if we measure hormones in eumenorrhoeic infertile patients?

By Nawroth Frank   Ludwig Michael  

Reproductive BioMedicine Online, Vol. 16, Iss. 5, 2008-05 ,pp. : 621-626

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Renal Transplantation in High-Risk Patients

By Weimert Nicole A.  

Drugs, Vol. 67, Iss. 11, 2007-01 ,pp. : 1603-1627

Adis International

Access to resources Recommend Favorite

What can the clinician do to improve implantation?

By Boomsma CM   Macklon NS  

Reproductive BioMedicine Online, Vol. 13, Iss. 6, 2006-12 ,pp. : 845-855

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease

By Vogt Anja   Parhofer Klaus G  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 6, 2013-04 ,pp. : 691-697

Informa Healthcare

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Inhaled Zanamivir in the Treatment of Influenza A and B in High-Risk Patients

By Griffin A.D.  

PharmacoEconomics, Vol. 19, Iss. 3, 2001-03 ,pp. : 293-301

Adis International

Access to resources Recommend Favorite